Paul M. Krzyzanowski

TL;DR: Deep sequencing is used to analyse genes that are recurrently mutated in AML to distinguish between individuals who have a high risk of developing AML and those with benign ARCH, providing proof-of-concept that it is possible to discriminate ARCH from pre-AML many years before malignant transformation.

TL;DR: Prospective genomic profiling of advanced PDAC is feasible, and early data indicate that chemotherapy response differs among patients with different genomic/transcriptomic subtypes.

TL;DR: This study identified essential gene profiles in 72 breast, pancreatic, and ovarian cancer cell lines using a lentiviral shRNA library targeting ~16,000 genes and a newly developed, dynamic scoring approach, to facilitate the systematic identification of drivers, unanticipated synthetic lethal relationships, and functional vulnerabilities of these tumor types.

TL;DR: Whole-genome sequencing, transcriptome sequencing and single-cell analysis of primary and metastatic pancreatic adenocarcinoma identify molecular subtypes and intratumor heterogeneity, and support the premise that the constellation of genomic aberrations in the tumor gives rise to the molecular subtype.

TL;DR: It is shown that Tankyrase, a member of the poly(ADP-ribose)polymerase (PARP) family, regulates 3BP2 stability through ADp-ribosylation and subsequent ubiquitylation by the E3-ubiquitin ligase RNF146 in osteoclasts.